Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist

A 10-year Observational Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01338662

Enrollment

500

Registered

2011-04-19

Start date

2011-05-31

Completion date

2022-04-30

Last updated

2017-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease

Brief summary

The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson's disease.

Detailed description

1. Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment. 2. Prospective , randomized, open label study compare the onset time and severity of dyskinesia between groups randomized assigned order of amantadine and dopamine agonist

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Inclusion criteria

* 30\<age\<60 * IPD * H & Y\<3

Exclusion criteria

* previous dopaminergic medication history * dyskinesia * Parkinson plus * clinically significant or unstable medical or surgical condition

Design outcomes

Primary

Measure	Time frame	Description
dyskinesia onset	up to 10 years from the start of durg (Amantadine or dopaimine agonsit)	observe duration of onset of dyskinesia from initial treatment observe until 10 years

Secondary

Measure	Time frame	Description
UPDRS, severity of dyskinesia between groups	observe duration of onset of dyskinesia from initial treatment	observe duration of onset of dyskinesia from initial treatment observe until 10 years compare the UPDRS and severity of dyskinesia between groups

Countries

South Korea

Contacts

Primary ContactBeom S Jeon, MD, PhD

brain@snu.ac.kr82-2-2072-2876

Backup ContactYoung Eun Kim, MD

yeksl99@hanmail.net82-2-2072-1219

Outcome results